Smithfield Trust’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Smithfield Trust’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,613	Closed	-$371K	–	962
2018 Q4	$371K	Hold	6,613	–	–	0.04%	161
2018 Q3	$541K	Sell	6,613 -2,631	-28%	-$185K	0.06%	147
2018 Q2	$323K	Hold	9,244	–	–	0.04%	198
2018 Q1	$190K	Hold	9,244	–	–	0.02%	282
2017 Q4	$262K	Hold	9,244	–	–	0.03%	231
2017 Q3	$287K	Hold	9,244	–	–	0.04%	216
2017 Q2	$292K	Hold	9,244	–	–	0.04%	217
2017 Q1	$209K	Hold	9,244	–	–	0.03%	261
2016 Q4	$202K	Buy	9,244 +4,498	+95%	+$114K	0.03%	280
2016 Q3	$125K	Hold	4,746	–	–	0.02%	357
2016 Q2	$94K	Buy	+4,746	New	+$92.3K	0.02%	397

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Smithfield Trust's RETA Position: Q1 2019 in Review

Smithfield Trust sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2019, closing a stake of 6,613 shares — an estimated $371K sold.

Smithfield Trust first reported a position in RETA in Q2 2016 and held it in 11 quarters. The position peaked at $541K in Q3 2018. 157 funds tracked by Wall St. Rank hold RETA as of Q1 2019.

Smithfield Trust reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2019 after selling out during the quarter.
Smithfield Trust sold 6,613 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2019, an estimated $371K.
Smithfield Trust first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 11 quarters.
Smithfield Trust's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $541K in Q3 2018.
157 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2019.

Based on Smithfield Trust's 13F filing for Q1 2019, filed 30 Apr 2019.